Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2014
Price : $35 *
At a glance
- Drugs MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Jan 2014 According to ClinicalTrials.gov record planned end date changed from 1 Jun 2018 to 1 Jan 2018.